Companies To Watch
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
-
Companies To Watch: Freya Biosciences
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
-
Companies To Watch: Spruce Biosciences
Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.
-
Companies To Watch: Nido Biosciences
See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.
-
Companies To Watch: Ventoux Biosciences
Why Ventoux Biosciences is pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases.
-
Companies To Watch: Kinaset Therapeutics
Kinaset Therapeutics is moving fast in the respiratory space to advance a potential first-time therapy.
-
Companies To Watch: Orca Bio
Orca Bio is creating a new cell therapy aimed at bringing rebirth to stem-cell transplantation.
-
Companies To Watch: Sonoma Biotherapeutics
Sonoma Biotherapeutics is bioengineering T cells to create potential cures for autoimmune and inflammatory conditions.
-
Companies To Watch: KaliVir Immunotherapeutics
KaliVir Immunotherapeutics is engineering oncolytic viruses with novel transgenes, and joining them to other immunotherapies, to defeat cancer and cancer relapse.
-
Companies To Watch: Hummingbird Bioscience
Hummingbird Bioscience is joining the forces of computational and systems biology to fight cancer and autoimmune disease.
-
Companies To Watch: Corner Therapeutics
Corner Therapeutics is focused on discovering new small molecules that could mimic the body’s natural immune response to generate the robust T-cell response.
-
Companies To Watch: Ocelot Bio
Ocelot Bio is focusing a single drug on multiple complications of end-stage liver disease.
-
Companies To Watch: iTolerance
iTolerance is dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation.
-
Companies To Watch: CytoAgents
CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.
-
Companies To Watch: Viking Therapeutics
Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.
IN THIS MONTH'S ISSUE
BEYOND THE PRINTED PAGE
-
2023 Manufacturing And Supply Chain Outlook: Additional Insights12/16/2022
Additional executive responses to our 2023 manufacturing and supply chain outlook questions.
-
2023 Finance And Funding Outlook: Additional Insights Part 212/9/2022
Additional experts weigh in on Life Science Leader's 2023 finance and funding outlook questions.
-
2023 Finance And Funding Outlook: Additional Insights Part 112/2/2022
Biopharma executives offer options, tips and strategies for navigating finance and funding challenges in 2023.